• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
NewslettersBrainstorm Health

Amazon’s Alexa can now give you detailed information on your medications

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
March 3, 2020, 12:02 PM ET

This is the web version of Brainstorm Health Daily, Coins2Day’s daily newsletter on the top health care news. To get it delivered daily to your in-box, sign up here.

Good morning, readers.

Some busy times here with the cascade of news surrounding the coronavirus (stay tuned for a big dispatch on that soon—and follow all of Coins2Day‘s coverage of this public health threat here).

But I did want to share an interesting digital health development. Amazon, which has been steadily expanding its medical ambitions via its moves into the online pharmacy space and, notably, HIPAA compliance for its voice-activated Alexa service, has struck a new medical information partnership with First Databank.

With this alliance, Alexa will be able to answer questions about drug safety, side effects, and drug-on-drug interactions.

“We are proud to bring this essential component of our drug databases directly to consumers through Amazon’s now-ubiquitous and helpful voice-activated technology,” said Bob Katter, president of First Databank, in a statement.

Read on for the day’s news.

Sy Mukherjee
[email protected]
@the_sy_guy

DIGITAL HEALTH

VistaScan gets FDA clearance for smartphone ultrasounds. The Food and Drug Administration (FDA) has granted clearance to Emagine Solutions Technology's smartphone ultrasound application, dubbed the VistaScan mobile ultrasound system. To be clear, it's not like physicians can just wave their smartphones over a patient—there are probes that must be linked to the tech. But it does allow them to see ultrasound images in real time on ultrasounds and tablets, which can prove critical during an emergency situation. (Medgadget)

INDICATIONS

Novartis' Sandoz unit to pay $195 million fine in landmark antitrust case. Sandoz, the generic drug arm of Swiss pharma giant Novartis, will pay a nearly $200 million fine over a price fixing scandal that's been brewing for more than six years. Sandoz will have to admit guilt as part of the settlement, and the Justice Department says the fine is the largest of its kind for a domestic antitrust suit. (The Associated Press)

THE BIG PICTURE

Supreme Court to take up high stakes Obamacare case (again).  To use an outdated reference, Obamacare is a flat circle. Yes, the Affordable Care Act, signed into law ten years ago, is heading to the Supreme Court yet again. The Trump administration has been supporting a lawsuit to scrap the entirety of the law after the repeal of its individual insurance mandate. What the justices will focus on in this latest challenge to the ACA is whether or not that clause is "severable" from the rest of the health law, including its protections for Americans with pre-existing conditions and expansion of Medicaid.

REQUIRED READING

Jack Welch: For a time, the most valuable CEO on earth, by Geoff Colvin

The stock market's gyrations feel historic. But are they?, by Ben Carlson

Everything you wanted to know about Super Tuesday but were afraid to ask, by Nicole Goodkind

Sign up for other Coins2Day newsletters.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.